PFS Investments Inc. raised its stake in Pfizer Inc. (NYSE:PFE – Get Rating) by 10.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 114,320 shares of the biopharmaceutical company’s stock after acquiring an additional 10,570 shares during the period. PFS Investments Inc.’s holdings in Pfizer were worth $5,918,000 as of its most recent SEC filing.
A number of other institutional investors have also recently modified their holdings of the stock. Worth Asset Management LLC bought a new position in shares of Pfizer during the first quarter valued at $29,000. Rinkey Investments bought a new position in shares of Pfizer during the fourth quarter valued at $32,000. Stuart Chaussee & Associates Inc. lifted its holdings in shares of Pfizer by 108.3% during the first quarter. Stuart Chaussee & Associates Inc. now owns 625 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 325 shares in the last quarter. Advanced Research Investment Solutions LLC lifted its holdings in shares of Pfizer by 339.3% during the first quarter. Advanced Research Investment Solutions LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 509 shares in the last quarter. Finally, Bivin & Associates Inc. bought a new position in shares of Pfizer during the fourth quarter valued at $37,000. 67.90% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of research analysts have recently issued reports on PFE shares. Berenberg Bank set a $50.00 price target on Pfizer in a report on Friday, May 27th. The Goldman Sachs Group set a $50.00 target price on Pfizer in a report on Thursday, September 1st. Morgan Stanley lowered their target price on Pfizer from $52.00 to $49.00 and set an “equal weight” rating on the stock in a report on Friday, July 8th. UBS Group set a $59.00 target price on Pfizer in a report on Thursday, September 1st. Finally, JPMorgan Chase & Co. set a $57.00 target price on Pfizer in a report on Tuesday, June 28th. Nine research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and a consensus price target of $57.33.
Pfizer Stock Performance
NYSE PFE opened at $47.84 on Monday. The stock has a market capitalization of $268.49 billion, a PE ratio of 9.36, a P/E/G ratio of 0.59 and a beta of 0.70. Pfizer Inc. has a 1-year low of $40.94 and a 1-year high of $61.71. The business has a 50 day simple moving average of $49.61 and a two-hundred day simple moving average of $50.49. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.42 and a quick ratio of 1.20.
Pfizer (NYSE:PFE – Get Rating) last posted its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.95 by $0.09. The business had revenue of $27.74 billion during the quarter, compared to analyst estimates of $26.20 billion. Pfizer had a return on equity of 43.18% and a net margin of 28.92%. The company’s revenue for the quarter was up 46.8% on a year-over-year basis. During the same period last year, the company earned $1.07 EPS. On average, research analysts predict that Pfizer Inc. will post 6.54 EPS for the current fiscal year.
Pfizer Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Stockholders of record on Wednesday, June 29th were paid a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 3.34%. The ex-dividend date was Thursday, July 28th. Pfizer’s payout ratio is 31.31%.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.